Max Wolf

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Marinus H. J. van Oers, Richard Klasa, Robert Marcus et al. · Blood · 2006 · 592 citations · Full text

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Marinus H. J. van Oers, M. van Glabbeke, L. Giurgea et al. · Journal of Clinical Oncology · 2010 · 336 citations

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

Michael Pfreundschuh, Anthony D. Ho, Eva Cavallin‐Ståhl et al. · The Lancet Oncology · 2008 · 221 citations

Hematological Malignancy, Lymphoid Neoplasia, Maximum Tumour +9

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

Graham M. Mead, Sharon Barrans, Wendi Qian et al. · Blood · 2008 · 214 citations · Full text

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma

Andrew Wirth, John F. Seymour, Rodney J. Hicks et al. · The American Journal of Medicine · 2002 · 170 citations

Positron Emission Tomography, Lymphoid Neoplasia, Conventional Staging +9